Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. More Details
Weak fundamentals or lack of information.
Share Price & News
How has Sun Pharma Advanced Research's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SPARC has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: SPARC underperformed the Indian Pharmaceuticals industry which returned 52.6% over the past year.
Return vs Market: SPARC exceeded the Indian Market which returned 2.2% over the past year.
Price Volatility Vs. Market
How volatile is Sun Pharma Advanced Research's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Shareholder Ownership Skewed Towards Insiders?
6 months ago | Simply Wall StWhat Kind Of Investor Owns Most Of Sun Pharma Advanced Research Company Limited (NSE:SPARC)?
Is Sun Pharma Advanced Research undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Sun Pharma Advanced Research is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sun Pharma Advanced Research has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of SPARC's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Sun Pharma Advanced Research regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Sun Pharma Advanced Research forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sun Pharma Advanced Research has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of SPARC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Sun Pharma Advanced Research competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Sun Pharma Advanced Research performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SPARC is currently unprofitable.
Growing Profit Margin: SPARC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SPARC is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.
Accelerating Growth: Unable to compare SPARC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPARC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).
Return on Equity
High ROE: SPARC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Sun Pharma Advanced Research's financial position?
Financial Position Analysis
Short Term Liabilities: SPARC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: SPARC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: SPARC has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: SPARC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPARC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SPARC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27.2% each year
What is Sun Pharma Advanced Research current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SPARC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPARC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SPARC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPARC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SPARC's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Anil Raghavan has been the Chief Executive Officer of Sun Pharma Advanced Research Company Limited since April 24, 2014. Mr. Raghavan is a senior pharmaceutical services executive with significant glob ...
|Chairman & MD||8.58yrs||no data||10.74% |
|Chief Financial Officer||3.67yrs||₹15.14m||0.0039% |
|Compliance Officer & Company Secretary||5.42yrs||₹3.37m||no data|
|Chief Executive Officer||6.5yrs||no data||no data|
|Chief Human Resource Officer||0.75yr||no data||no data|
|Senior Vice President||no data||no data||no data|
|Senior Vice President of R&D||no data||no data||no data|
|Executive Vice President of R&D (Formulation Development)||no data||no data||no data|
|Senior Vice President of Clinical Development & Operations||no data||no data||no data|
|Senior VP & Chief Innovation Officer||no data||no data||no data|
|Vice President and Head of Dermatology & Rheumatology||no data||no data||no data|
|VP & Head of Translational Development||1.5yrs||no data||no data|
Experienced Management: SPARC's management team is considered experienced (4.5 years average tenure).
|Chairman & MD||8.58yrs||no data||10.74% |
|Non-Executive Director||14.58yrs||₹390.00k||2.28% |
|Additional Independent Director||0.33yr||no data||no data|
|Independent Director||5.17yrs||₹600.00k||no data|
|Non-Executive Director||13.33yrs||₹270.00k||0.014% |
|Additional Independent Director||3.42yrs||₹570.00k||no data|
Experienced Board: SPARC's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Sun Pharma Advanced Research Company Limited's company bio, employee growth, exchange listings and data sources
- Name: Sun Pharma Advanced Research Company Limited
- Ticker: SPARC
- Exchange: NSEI
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹43.893b
- Shares outstanding: 262.05m
- Website: https://www.sparc.life
Number of Employees
- Sun Pharma Advanced Research Company Limited
- 17-B, Mahal Industrial Estate
- Off Mahakali Caves Road
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|532872||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Jul 2007|
|SPARC||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Jul 2007|
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. The company develops new chemical entities or reformulated prod ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/20 12:42|
|End of Day Share Price||2020/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.